{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:23:04Z","timestamp":1794446584744,"version":"4.9.1"},"reference-count":36,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,13]]},"DOI":"10.20945\/2359-4292-2022-0334","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T17:48:39Z","timestamp":1699984119000},"source":"Crossref","is-referenced-by-count":60,"title":["Long-term consequences of osteoporosis therapy with bisphosphonates"],"prefix":"10.20945","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3552-0896","authenticated-orcid":false,"given":"B\u00e1rbara","family":"Gehrke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7744-5604","authenticated-orcid":false,"given":"Maria Caroline Alves","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7332-9841","authenticated-orcid":false,"given":"Catarina Brasil","family":"d'Alva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6752-2880","authenticated-orcid":false,"given":"Miguel","family":"Madeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"issue":"12","key":"key20231114124831_B1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2146\/ajhp090506","article-title":"Risks and benefits of long-term bisphosphonate therapy","volume":"67","author":"Schmidt","year":"2010","unstructured":"Schmidt GA, Horner KE, McDanel DL, Ross MB, Moores KG. Risks and benefits of long-term bisphosphonate therapy. Am J Health Syst Pharm. 2010;67(12):994-1001. doi: 10.2146\/ajhp090506.","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"key20231114124831_B2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243-54. doi: 10.1002\/jbmr.1494.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"key20231114124831_B3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","unstructured":"Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010;25(5):976-82. doi: 10.1002\/jbmr.11.","journal-title":"J Bone Miner Res"},{"issue":"9041","key":"key20231114124831_B4","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535-41. doi: 10.1016\/s0140-6736(96)07088-2.","journal-title":"Lancet"},{"issue":"12","key":"key20231114124831_B5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189-99. doi: 10.1056\/NEJMoa030897.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20231114124831_B6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","unstructured":"McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126(1):13-20. doi: 10.1016\/j.amjmed.2012.06.023.","journal-title":"Am J Med"},{"issue":"9","key":"key20231114124831_B7","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032-45. doi: 10.4065\/83.9.1032.","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"key20231114124831_B8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","unstructured":"Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004;15(10):792-8. doi: 10.1007\/s00198-004-1602-9.","journal-title":"Osteoporos Int"},{"issue":"8","key":"key20231114124831_B9","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","unstructured":"Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241-9. doi: 10.1359\/JBMR.040325.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"key20231114124831_B10","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1345\/aph.1E357","article-title":"Discovery, clinical development, and therapeutic uses of bisphosphonates","volume":"39","author":"Licata","year":"2005","unstructured":"Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother. 2005;39(4):668-77. doi: 10.1345\/aph.1E357.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"key20231114124831_B11","first-page":"664","article-title":"Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis \u2013 A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso)","volume":"64","author":"Madeira","year":"2021","unstructured":"Madeira M, Rocha AC, Moreira CA, Aguiar AMM, Maeda SS, Cardoso AS, et al. Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis \u2013 A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso). Arch Endocrinol Metab. 2021;64(6):664-72. doi: 10.20945\/2359-3997000000301.","journal-title":"Arch Endocrinol Metab"},{"key":"key20231114124831_B12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/bonekey.2014.24","article-title":"Bisphosphonates and bone quality","volume":"3","author":"Pazianas","year":"2014","unstructured":"Pazianas M, van der Geest S, Miller P. Bisphosphonates and bone quality. Bonekey Rep. 2014;3:529. doi: 10.1038\/bonekey.2014.24","journal-title":"Bonekey Rep"},{"issue":"4","key":"key20231114124831_B13","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10476","article-title":"A Bisphosphonate with a Low Hydroxyapatite Binding Affinity Prevents Bone Loss in Mice After Ovariectomy and Reverses Rapidly with Treatment Cessation","volume":"5","author":"Coffman","year":"2021","unstructured":"Coffman AA, Basta-Pljakic J, Guerra RM, Ebetino FH, Lundy MW, Majeska RJ, et al. A Bisphosphonate with a Low Hydroxyapatite Binding Affinity Prevents Bone Loss in Mice After Ovariectomy and Reverses Rapidly with Treatment Cessation. JBMR Plus. 2021;5(4):e10476. doi: 10.1002\/jbm4.10476.","journal-title":"JBMR Plus"},{"key":"key20231114124831_B14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bone.2013.09.023","article-title":"Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review","volume":"58","author":"Eriksen","year":"2014","unstructured":"Eriksen EF, Diez-Perez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone. 2014;58:126-35. doi: 10.1016\/j.bone.2013.09.023.","journal-title":"Bone"},{"issue":"24","key":"key20231114124831_B15","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures","volume":"296","author":"Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-38. doi: 10.1001\/jama.296.24.2927.","journal-title":"JAMA"},{"issue":"11","key":"key20231114124831_B16","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/jbmr.5650101122","article-title":"Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures","volume":"10","author":"Ensrud","year":"1995","unstructured":"Ensrud KE, Palermo L, Black DM, Cauley J, Jergas M, Orwoll ES, et al. Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures. J Bone Miner Res. 1995;10(11):1778-87. doi: 10.1002\/jbmr.5650101122.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"key20231114124831_B17","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","unstructured":"Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30(5):934-44. doi: 10.1002\/jbmr.2442.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"key20231114124831_B18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstr\u00f6m","year":"2004","unstructured":"Mellstr\u00f6m DD, S\u00f6rensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75(6):462-8. doi: 10.1007\/s00223-004-0286-7.","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"key20231114124831_B19","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/jbmr.2918","article-title":"Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(10):1910. doi: 10.1002\/jbmr.2918.","journal-title":"J Bone Miner Res"},{"issue":"11","key":"key20231114124831_B20","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","unstructured":"Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267-94. doi: 10.1002\/jbmr.253.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"key20231114124831_B21","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294-301. doi: 10.1210\/jc.2004-0952.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20231114124831_B22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.rbr.2017.06.001","article-title":"Brazilian guidelines for the diagnosis and treatment of postmenopausal osteoporosis","volume":"57","author":"Radominski","year":"2017","unstructured":"Radominski SC, Bernardo W, Paula AP, Albergaria BH, Moreira C, Fernandes CE, et al. Brazilian guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Rev Bras Reumatol Engl Ed. 2017;57 Suppl 2:452-66. doi: 10.1016\/j.rbre.2017.07.001.","journal-title":"Rev Bras Reumatol Engl Ed"},{"issue":"4","key":"key20231114124831_B23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11914-018-0464-6","article-title":"Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures","volume":"16","author":"Starr","year":"2018","unstructured":"Starr J, Tay YKD, Shane E. Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures. Curr Osteoporos Rep. 2018;16(4):519-29. doi: 10.1007\/s11914-018-0464-6.","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"key20231114124831_B24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1186\/s12891-020-03672-w","article-title":"Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years","volume":"21","author":"Lo","year":"2020","unstructured":"Lo JC, Neugebauer RS, Ettinger B, Chandra M, Hui RL, Ott SM, et al. Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. BMC Musculoskelet Disord. 2020;21(1):801. doi: 10.1186\/s12891-020-03672-w.","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"key20231114124831_B25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/17453674.2015.1004149","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"86","author":"Schilcher","year":"2015","unstructured":"Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015;86(1):100-7. doi: 10.3109\/17453674.2015.1004149.","journal-title":"Acta Orthop"},{"issue":"4","key":"key20231114124831_B26","first-page":"324","article-title":"Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays","volume":"60","author":"Brown","year":"2014","unstructured":"Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014;60(4):324-33.","journal-title":"Can Fam Physician"},{"issue":"3","key":"key20231114124831_B27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jbmr.233","article-title":"Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007","volume":"26","author":"Wang","year":"2011","unstructured":"Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res. 2011;26(3):553-60. doi: 10.1002\/jbmr.233.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"key20231114124831_B28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4081\/reumatismo.2017.983","article-title":"Drug-induced osteonecrosis of the jaw: the state of the art","volume":"69","author":"Fassio","year":"2017","unstructured":"Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D. Drug-induced osteonecrosis of the jaw: the state of the art. Reumatismo. 2017;69(1):9-15. doi: 10.4081\/reumatismo.2017.983.","journal-title":"Reumatismo"},{"issue":"1","key":"key20231114124831_B29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23. doi: 10.1002\/jbmr.2405.","journal-title":"J Bone Miner Res"},{"issue":"10","key":"key20231114124831_B30","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1007\/s00198-017-4132-y","article-title":"Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users","volume":"28","author":"Eiken","year":"2017","unstructured":"Eiken PA, Prieto-Alhambra D, Eastell R, Abrahamsen B. Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. Osteoporos Int. 2017;28(10):2921-8. doi: 10.1007\/s00198-017-4132-y.","journal-title":"Osteoporos Int"},{"issue":"2","key":"key20231114124831_B31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jebdp.2016.05.007","article-title":"Bisphosphonates, Osteoporosis, and Osteonecrosis of the Jaw: A Critical Review of a Large Nested Case-Control Study","volume":"16","author":"Zavras","year":"2016","unstructured":"Zavras AI, Shanmugham JR. Bisphosphonates, Osteoporosis, and Osteonecrosis of the Jaw: A Critical Review of a Large Nested Case-Control Study. J Evid Based Dent Pract. 2016;16(2):136-8. doi: 10.1016\/j.jebdp.2016.05.007.","journal-title":"J Evid Based Dent Pract"},{"issue":"1","key":"key20231114124831_B32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00774-019-01035-7","article-title":"Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw","volume":"38","author":"Hayashida","year":"2020","unstructured":"Hayashida S, Yanamoto S, Fujita S, Hasegawa T, Komori T, Kojima Y, et al. Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw. J Bone Miner Metab. 2020;38(1):126-34. doi: 10.1007\/s00774-019-01035-7.","journal-title":"J Bone Miner Metab"},{"issue":"12","key":"key20231114124831_B33","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/jbmr.3237","article-title":"Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study","volume":"32","author":"Jung","year":"2017","unstructured":"Jung J, Yoo HY, Kim GT, Lee JW, Lee YA, Kim DY, et al. Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study. J Bone Miner Res. 2017;32(12):2445-52. doi: 10.1002\/jbmr.3237.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"key20231114124831_B34","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.ijom.2015.07.018","article-title":"Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings","volume":"44","author":"Kakehashi","year":"2015","unstructured":"Kakehashi H, Ando T, Minamizato T, Nakatani Y, Kawasaki T, Ikeda H, et al. Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings. Int J Oral Maxillofac Surg. 2015;44(12):1558-64. doi: 10.1016\/j.ijom.2015.07.018.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"5","key":"key20231114124831_B35","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update","volume":"80","author":"Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022;80(5):920-43. doi: 10.1016\/j.joms.2022.02.008.","journal-title":"J Oral Maxillofac Surg"},{"issue":"5","key":"key20231114124831_B36","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1210\/clinem\/dgz295","article-title":"Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations from the European Calcified Tissue Society","volume":"105","author":"van de Laarschot","year":"2020","unstructured":"van de Laarschot DM, McKenna MJ, Abrahamsen B, Langdahl B, Cohen-Solal M, Guanabens N, et al. Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations from the European Calcified Tissue Society. J Clin Endocrinol Metab. 2020;105(5):1682-99. doi: 10.1210\/clinem\/dgz295.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T17:49:00Z","timestamp":1699984140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/long-term-consequences-of-osteoporosis-therapy-with-bisphosphonates\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":36,"alternative-id":["10.20945\/2359-4292-2022-0334"],"URL":"https:\/\/doi.org\/10.20945\/2359-4292-2022-0334","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"article-number":"e220334"}}